Valproic AcId for Traumatic BRAin INjury Trial

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

February 28, 2030

Study Completion Date

December 31, 2030

Conditions
Moderate Traumatic Brain Injury (TBI)Severe Traumatic Brain Injury
Interventions
DRUG

Valproic Acid (VPA)

VPA (in 250 ml 0.9% sodium chloride solution)

OTHER

Standard of care treatment + normal saline

Standard of care treatment + normal saline (0.9% sodium chloride solution) vehicle (250 ml)

Trial Locations (8)

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

53226

Medical College of Wisconsin, Milwaukee

75390

University of Texas Southwestern, Dallas

95817

University of California, Davis, Sacramento

97239

Oregon Health & Science University, Portland

85719-4824

University of Arizona, Tucson

90089-0701

University of Southern California, Los Angeles

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Northwestern University

OTHER

NCT07166393 - Valproic AcId for Traumatic BRAin INjury Trial | Biotech Hunter | Biotech Hunter